Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
You have been diagnosed with MGUS, SMM or Multiple Myeloma (MM). What if you could fight your MM AND lose weight at the same time? What if foods that fight multiple myeloma were incorporated into your daily meal plan? According to the studies below, loosing those unwanted pounds can help you reduce angiogenesis and achieve complete remission from your multiple myeloma.
When I talk about foods that fight MM, I’m talking about anti- angiogenic foods and supplements. I eat these foods daily. I take these supplements daily. I reached complete remission in early 1999 and have remaining in CR ever since.
The foods that fight MM that I eat daily-
The fact is that common MM chemotherapy regimens such as
are referred to as angiogenic inhibitor chemotherapy drugs. While there are no chemotherapy regimens that are designed to make the cancer patient loose weight, as the article linked and excerpted below states, losing weight is a great way to reduce the risk of cancer or a cancer relapse.
I am both a long-term MM survivor and MM cancer coach. I have been living an antiangiogenic and anti-inflammatory lifestyle through nutrition and supplementation for years now. Do you think my losing 20 pounds since I reached complete remission in 1999 has helped me remain in complete remission?
Have you been diagnosed with multiple myeloma? Do you want to loose weight and put your cancer into complete remission? Scroll down the page, post a question or a comment and I will reply to you ASAP.
“In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.
“Once a person with cancer is out of the normal weight category, their BMI is contributing to multiple myeloma growth and progression,” said Katie DeCicco-Skinner, associate professor of biology at American University and lead study author.
DeCicco-Skinner and her colleagues examined the BMI of normal, overweight, obese and morbidly obese patients, and the effects on multiple myeloma. Little research into multiple myeloma examines varying patient weight to see how cells encourage cancer growth. Even fewer studies examine cancer and the morbidly obese — a fourth weight category DeCicco-Skinner said was important to study, as more overweight individuals today have the condition…
Cultivating stem cells
The researchers obtained stem cells from the discarded fat of liposuction patients who underwent elective surgery. They turned them into fat cells and cultured the fat cells with multiple myeloma. In bone marrow, where multiple myeloma often takes root, fat cells play an important role in the proliferation, survival, progression and drug resistance of the cancer cells.
As a patient’s BMI increases, fat cells communicate with multiple myeloma cells, researchers found. Fat cells grow larger, gain additional lipid and secrete proteins linked to cancer. The researchers also found a correlation between BMI and angiogenesis and adhesion, key indicators of progression.
“We know multiple myeloma cells will anchor into bone marrow, and fat cells in the bone marrow will support the growth and spread of the cancer. In our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,” DeCicco-Skinner explained. “With angiogenesis, cancer cells cannot exist without their own blood supply. We also found the amount of blood vessels that developed was directly proportional to a patient’s BMI.”
DeCicco-Skinner and her colleagues assumed cancer proliferation would benefit from higher-than-normal BMI because of the epidemiological link between obesity and cancer. But the relationship between multiple myeloma and the BMI of obese and morbidly obese patients was drastic.
“We found that fat cells from obese or morbidly obese patients secreted a high amount of inflammatory proteins, which contributed to tumor progression,” DeCicco-Skinner said.
Implications for treatment
DeCicco-Skinner’s research suggests a new approach for the treatment of multiple myeloma. Physicians may want to consider tailoring drugs based on a patient’s BMI because a drug may not be as effective in obese or morbidly obese patients.
“Most people think if you develop multiple myeloma, you go to the doctor, find out what the most effective drug cocktail is and how it will affect you,” DeCicco-Skinner said. “A patient may need to receive drugs to block inflammatory or other obesity-specific proteins, in addition to standard anti-cancer drugs they receive.”
Whether investigating fat cells, immunotherapy or use of the CRISPR-Cas 9 gene-editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers. With multiple myeloma, most patients live four to seven years from their date of diagnosis, and most become resistant to chemotherapy drugs over time.
“Obesity increasingly plays a role in cancer cases as the numbers of those who are obese rise. Improving our understanding of how fat cells and cancer cells communicate with each other, and how the communication changes during obesity, is critical,” DeCicco-Skinner said.”